Adding Obinutuzumab to Acalabrutinib-Venetoclax for CLL
July 24, 2025
Adding early Obinutuzumab to Acalabrutinib-Venetoclax significantly increases rates of uMRD in the bone marrow of patients with treatment-naïve CLL.
Adding early Obinutuzumab to Acalabrutinib-Venetoclax significantly increases rates of uMRD in the bone marrow of patients with treatment-naïve CLL.
Combination ibrutinib-venetoclax-obinutuzumab provided short-term control for patients with Richter’s transformation, but responses were not durable.
Atezolizumab-venetoclax-obinutuzumab produced high remission rates, but immune-related side effects limit its usefulness as a frontline CLL therapy.
Patients with CLL who were able to rapidly clear measurable residual disease (MRD) needed less treatment and experienced longer remissions.
The first-line combination pirtobrutinib, venetoclax, and obinutuzumab produces deep remissions in the majority of patients with CLL.
Data suggests that patients with CLL who are on venetoclax plus obinutuzumab and reach undetectable MRD may be able to discontinue therapy early.
Acalabrutinib, venetoclax, and obinutuzumab is a highly active, time-limited frontline therapy for patients with high-risk CLL.
Acalabrutinib plus obinutuzumab had a 100 percent response rate at 14 months and a deep reduction of disease in the bone marrow in treatment-naive CLL.
An interim analysis of the AMPLIFY trial comparing acalabrutinib and venetoclax with or without obinutuzumab for CLL shows improvements in patient survival.